 |
市場調查報告書
商品編碼
2008075
降血糖藥物市場：依藥物類別、給藥途徑、分銷管道及地區分類。Hypoglycemic Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
預計到2026年，降血糖藥物市場規模將達到9.052億美元，到2033年將達到12.706億美元。預計從2026年到2033年，該市場將以9.6%的複合年成長率成長。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2025 | 市場規模（2026 年） | 9.052億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2026-2033 |
| 預測期（2026-2033 年）複合年成長率 | 9.60% | 預計金額（2033 年） | 12.706億美元 |
低血糖是指血糖值低於正常範圍的一種狀態。葡萄糖是人體主要的能源來源。低血糖通常與糖尿病治療有關。當血液中葡萄糖濃度低於設定值（即 4 mmol/L (72 mg/dL)）時，就會發生低血糖。低血糖的症狀包括出汗、疲勞、頭暈、虛弱和視力模糊。低血糖可以透過使用血糖值儀測量血糖值來檢測。如果血糖值低於 4.0 mmol/L，則被認為處於低血糖狀態。
市場動態
糖尿病盛行率的上升預計將推動全球降血糖藥物市場的成長。例如，根據美國糖尿病協會2022年7月28日發表的報導，2019年美國有3,730萬人患有糖尿病，佔總人口的11.3%。其中約有190萬美國人患有第1型糖尿病，約24.4萬人為兒童及青少年。根據同一資訊來源的數據，每年有140萬美國人被診斷出患有糖尿病。此外，2014年至2015年，青少年糖尿病病例估計每年新增18,200例，其中1型糖尿病病例為18,200例，第2型糖尿病病例為5,800例。
監管機構核准的藥品數量增加預計將推動全球低血糖藥物市場的成長。例如，2020年12月，專業製藥公司Amphastar Pharmaceuticals, Inc.核准，美國食品藥物管理局（FDA）已批准其「緊急升糖素注射劑套裝（1毫克）」的新藥申請（ANDA）。升糖素用於治療嚴重低血糖，也可用作輔助診斷。
本報告的主要特點
- 本報告對全球降血糖藥物市場進行了詳細分析，包括預測期（2026-2033 年）的市場規模和複合年成長率，以 2025 年為基準年。
- 此外，它還確定了每個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
- 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本節根據以下參數，介紹全球降血糖藥物市場主要企業的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
- 《全球降血糖藥物市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過分析全球降血糖藥物市場中使用的各種策略矩陣來促進決策。
目錄
第1章：分析目標與假設
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 銷售代理商名單
- 主要進展
- PEST分析
- 法規環境
- 新產品上市及核准
- 企業併購與商業合作趨勢
- 市場趨勢
第4章：全球降血糖藥物市場：依藥物類別分類（2026-2033 年）
- 磺醯尿素類藥物
- 雙胍類
- α-Glucosidase酶抑制劑
- 胰島素增敏劑酮類
- Dipeptidyl Peptidase-4 (DPP-4) 抑制劑
- 升糖素
第5章：全球降血糖藥物市場：依給藥途徑分類（2026-2033 年）
- 口服
- 注射
- 鼻噴劑
第6章：全球降血糖藥物市場：依通路分類（2026-2033 年）
- 醫院藥房
- 零售藥房
- 網路藥房
第7章 全球降血糖藥物市場：按地區分類（2026-2033年）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 南非
- 中非
- 北非
第8章 競爭情勢
- 公司簡介
- Eli Lilly &Company
- Boehringer Ingelheim GmbH
- Vistin Pharma AS
- Janssen Pharmaceuticals NV
- Sanofi
- Astellas Pharma Inc.
- AstraZeneca plc.
- Merck &Co., Inc.
- Novartis AG
- Novo Nordisk A/S
- Teva Pharmaceutical Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
第9章
- 參考
- 分析方法
簡介目錄
Product Code: CMI5252
Hypoglycemic Drugs Market is estimated to be valued at USD 905.2 Mn in 2026 and is expected to reach USD 1,270.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 905.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.60% | 2033 Value Projection: | USD 1,270.6 Mn |
Hypoglycemia is a condition in which blood sugar (glucose) level is lower than the standard range. Glucose is the main energy soiurce for the body. Hypoglycemia is often related to diabetes treatment. Hypoglycemia occurs when the level of glucose present in the blood falls below a set point, i.e., below 4 mmol/L (72mg/dL). The symptoms associated with Hypogyclemia are, sweating, fatigue, feeling dizzy, feeling weak, blurred vision, and others. Hypoglycemia is detected by measuring blood sugar levels with a glucose meter. Any blood glucose level below 4.0 mmol/L indicates that the individual has hypoglycemia.
Market Dynamics
Increasing prevalence of diabetes is expected to drive growth of the global hypoglycemic drugs market. For instance, according to an article published by American Diabetes Association on 28 July 2022, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Nearly 1.9 million Americans had type 1 diabetes, including about 244,000 children and adolescents. 1.4 million Americans are diagnosed with diabetes every year.according to same soruce, In 2014-2015, the annual incidence of diagnosed diabetes in youth was estimated at 18,200 with type 1 diabetes and 5,800 with type 2 diabetes.
Increasing number of drug approvals from regulatory bodies is expected to drive growth of the global hypoglycemic drugs market. For instance, in December 2020, Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid.
Key features of the study
- This report provides an in-depth analysis of the global hypoglycemic drugs market, provides market size (USD Mn), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global hypoglycemic drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
- Key companies covered as a part of this study include Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceuticals NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and Sun Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global hypoglycemic drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global hypoglycemic drugs market
Market Segmentation
- Global Hypoglycemic Drugs Market, By Drug Class
- Sulphonylureas
- Biguanides
- Alpha-glucosidase inhibitors
- Thiazolidinediones (Glitazones)
- Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Glucagon
- Global Hypoglycemic Drugs Market, By Route of Administration
- Oral
- Injectable
- Nasal
- Global Hypoglycemic Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Hypoglycemic Drugs Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Eli Lilly & Company,
- Boehringer Ingelheim GmbH,
- Vistin Pharma AS,
- Janssen Pharmaceutica NV,
- Sanofi, Astellas Pharma Inc.,
- AstraZeneca plc.,
- Merck & Co., Inc.,
- Novartis AG.,
- Novo Nordisk A/S,
- Teva Pharmaceuticals Pvt Ltd.,
- Sun Pharmaceutical Industries Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- List of Distributors
- Key Developments
- PEST Analysis
- Regulatory Scenario
- New Product Launch/ Approval
- Acquisition and Partnership Scenario
- Market Trends
4. Global Hypoglycemic Drugs Market, By Drug Class, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
- Sulphonylureas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Biguanides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Alpha-glucosidase inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Thiazolidinediones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Dipeptidyl Peptidase-4 (DPP-4) inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Glucagon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
5. Global Hypoglycemic Drugs Market, By Route of Administration, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
6. Global Hypoglycemic Drugs Market, By Distribution Channel, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
7. Global Hypoglycemic Drugs Market, By Region, 2026 - 2033 (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country/ Region, 2026-2033 (USD Mn)
- South Africa
- Central Africa
- North Africa
8. Competitive Landscape
- Company Profiles
- Eli Lilly & Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Boehringer Ingelheim GmbH
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Vistin Pharma AS
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Janssen Pharmaceuticals NV
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Astellas Pharma Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AstraZeneca plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Novo Nordisk A/S
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Teva Pharmaceutical Pvt. Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Analyst Views
- Eli Lilly & Company
9. Section
- References
- Research Methodology
- About Us and Sales Contact
